Raymond J. Deshaies
Raymond J. Deshaies | |
|---|---|
| Born | September 25, 1961 |
| Alma mater | University of California, Berkeley (PhD) Cornell University (BS) |
| Known for | Discoveries of cullin–RING ubiquitin ligases and elucidation of their mechanism of action and regulation, the JAMM family of ubiquitin isopeptidases, PROTACs (heterobifunctional small molecules that promote target degradation) the Sec61 translocon, and nucleolar sequestration as a regulatory mechanism. Founder of Proteolix, which developed carfilzomib/Kyprolis® |
| Scientific career | |
| Fields | Biochemistry, Cell Biology |
| Institutions | Amgen California Institute of Technology |
| Doctoral advisor | Randy Schekman |
Raymond Joseph Deshaies (born September 25, 1961) is an American biochemist and cell biologist. He is a board director or member of the scientific advisory board of several biotechnology companies and an external affiliate at California Institute of Technology (Caltech). Previously, he was distinguished fellow and senior vice president of global research at Amgen. Prior to that, he was a professor of biology at Caltech and an investigator of the Howard Hughes Medical Institute. He is also the co-founder of the biotechnology companies Proteolix and Cleave Biosciences. His research focuses on mechanisms and regulation of protein homeostasis in eukaryotic cells, with a particular focus on how proteins are conjugated with ubiquitin and degraded by the proteasome.